Bisphosphonates

Jan 16, 2019

Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY(TM) (romosozumab)

Oct 31, 2018

Study: Denosumab Effective in Treating Osteoporosis in Transfusion-Dependent Thalassemia

Aug 03, 2018

Asia-Pacific Osteoporosis Therapeutics Markets 2018-2024: CAGR is Projected to Grow at 5.9%

Jun 13, 2018

Global Hypercalcemia Treatment Market to 2026: Adoption of Combination Therapy in Treatment of Hypercalcemia

Apr 03, 2018

European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

Feb 23, 2018

Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe

Jan 05, 2018

FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

Sep 08, 2017

Amgen Highlights The Latest EVENITY(TM) (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting

Jun 19, 2017

FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients

Jun 04, 2017

Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017